TABLE 2.
Maternal and infant adverse events1
| Adverse events | Carotenoid group (n = 24) | Control group (n = 23) |
|---|---|---|
| Maternal | ||
| Any adverse events | 6 | 8 |
| Gestational diabetes | 1 | 2 |
| Gestational hypertension | 1 | 0 |
| Preeclampsia | 0 | 2 |
| Anemia | 0 | 1 |
| Exacerbated acne | 1 | 0 |
| Itching | 1 | 0 |
| Torn placenta at delivery | 0 | 1 |
| Cholestasis | 0 | 1 |
| Sinus infection | 1 | 1 |
| Worsening depression | 1 | 1 |
| Nose laceration | 1 | 0 |
| COVID-19 | 2 | 1 |
| Preterm delivery2 | 1 | 0 |
| Infant | ||
| Small for gestational age | 1 | 0 |
| Heart murmur3 | 0 | 1 |
| Down syndrome2 | 1 | 0 |
| Multiple congenital anomalies2 | 1 | 0 |
Abbreviation: n, number of participants.
1
Adverse events after the initiation of the study intervention over the study duration for all 47 randomized subjects. Any adverse events represent the number of participants in each group that reported adverse events (which could be single or multiple for a participant).
2
Severe adverse events unrelated to study intervention.
3
Required no treatment.